Avalo Therapeutics, Inc. — Form D

Avalo Therapeutics, Inc. of ROCKVILLE, MD, a company, filed a Form D exempt-offering notice with the SEC on 2014-07-21. The offering totals $33.3M, of which $16.3M was reported sold. Industry: Biotechnology.

Offering

Issuer

Officers, directors & promoters (52)

Showing 25 of 52 people.

NameRoleLocation
Sol J BarerDirectorMendham, NJ
Blake M PatersonDirectorBaltimore, MD
Magnus A PerssonDirectorBaltimore, MD
Mayukh A SukhatmeDirectorBaltimore, MD
Frank A TortiDirectorMenlo Park, CA
Bernadine Heather FraserExecutive OfficerBaltimore, MD
John F KaiserExecutive OfficerBaltimore, MD
Reza F MazhariExecutive OfficerBaltimore, MD
Federica F O'BrienExecutive OfficerBaltimore, MD
Blake M PatersonExecutive OfficerBaltimore, MD
Sharon F RowlandExecutive OfficerMaryland, MD
James F VornovExecutive OfficerBaltimore, MD
John KaiserExecutive OfficerResearch Triangle Park, NC
Behshad SheldonDirectorMalvern, PA
CHRISTOPHER SULLIVANExecutive OfficerNew York, NY
Eugene BauerDirectorRedwood City, CA
Magnus PerssonDirectorBeachwood, OH
June Almenoff, M.D., Ph.D.DirectorRockville, MD
Mitchell ChanDirectorRockville, MD
Jonathan Goldman, M.D.DirectorRockville, MD
Aaron KantoffDirectorRockville, MD
Gilla Kaplan, Ph.D.DirectorRockville, MD
Magnus Persson, M.D., Ph.D.DirectorRockville, MD
Samantha TruexDirectorRockville, MD
Garry Neil, M.D.DirectorRockville, MD

Other filings by this issuer (5)

FiledFormOfferingSold
2024-04-09D$200.0M$130.6M
2017-05-08D$5.0M$5.0M
2016-09-16D$15.0M$1.0M
2013-09-06D$10.0M$6.8M
2012-04-04D$22.5M$22.1M

More